Antanasijevic et al., 2021 - Google Patents
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEMAntanasijevic et al., 2021
View HTML- Document ID
- 7535414578924217281
- Author
- Antanasijevic A
- Sewall L
- Cottrell C
- Carnathan D
- Jimenez L
- Ngo J
- Silverman J
- Groschel B
- Georgeson E
- Bhiman J
- Bastidas R
- LaBranche C
- Allen J
- Copps J
- Perrett H
- Rantalainen K
- Cannac F
- Yang Y
- de la Peña A
- Rocha R
- Berndsen Z
- Baker D
- King N
- Sanders R
- Moore J
- Crotty S
- Crispin M
- Montefiori D
- Burton D
- Schief W
- Silvestri G
- Ward A
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
Engineered ectodomain trimer immunogens based on BG505 envelope glycoprotein are widely utilized as components of HIV vaccine development platforms. In this study, we used rhesus macaques to evaluate the immunogenicity of several stabilized BG505 SOSIP …
- 230000002163 immunogen 0 title abstract description 42
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Antanasijevic et al. | Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM | |
| Xu et al. | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 | |
| Gorman et al. | Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design | |
| Medina-Ramírez et al. | Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo | |
| Torrents de la Peña et al. | Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics | |
| Ma et al. | Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies | |
| Flyak et al. | Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region | |
| Van Gils et al. | An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability | |
| Antanasijevic et al. | Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens | |
| Cohen et al. | Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers | |
| Hurlburt et al. | Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit | |
| McLellan et al. | Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | |
| Lee et al. | Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike | |
| Guenaga et al. | Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties | |
| Pancera et al. | Structure and immune recognition of trimeric pre-fusion HIV-1 Env | |
| Mao et al. | Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer | |
| Brouwer et al. | Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles | |
| Blais et al. | Characterization of Pre-F-GCN4t, a modified human respiratory syncytial virus fusion protein stabilized in a noncleaved prefusion conformation | |
| Schiffner et al. | Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins | |
| Cohen-Dvashi et al. | Structural basis for a convergent immune response against Ebola virus | |
| Wibmer et al. | Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions | |
| Chuang et al. | Development of a 3mut-apex-stabilized envelope trimer that expands HIV-1 neutralization breadth when used to boost fusion peptide-directed vaccine-elicited responses | |
| Fera et al. | HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope | |
| Liang et al. | Probing the impact of local structural dynamics of conformational epitopes on antibody recognition | |
| EP3518968B1 (en) | Hiv-1 env fusion peptide immunogens and their use |